- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02123186
Newborn Screening for Spinal Muscular Atrophy
October 31, 2016 updated by: National Taiwan University Hospital
To test if the routine newborn screening dried blood spots can be used to test if missing 2 copies of SMN1 gene, a status indicating spinal muscular atrophy
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Parents of newborns will be invited to test if their newborns are affected with SMA.
The routine newborn screening dried blood spots sample will be used to test if missing 2 copies of SMN1 gene.
If positive of screening test, further confirmation tests including physical examination and other methology for SMN1 gene copies quantification will be provided.
Genetic counseling and treatment option will be provided, too.
Study Type
Observational
Enrollment (Actual)
120267
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Taiwan,
-
Taipei, Taiwan,, Taiwan, 100
- National Taiwan University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
2 days to 3 months (CHILD)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
newborns whose parents agree to be tested
Description
Inclusion Criteria:
- Babies born in Taiwan receive regular new born screening suggested by Ministry of Heath and Welfare.
- Parents or Legal Guardian sign in the informed consent form.
Exclusion Criteria:
- Parents or Legal Guardian do not agree to sign in the informed consent form.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
newborns testing for SMA
|
Routine newborn screening dried blood spots sample is used to test if missing 2 copies of SMN1 gene.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
numbers of newborn with spinal muscular atrophy
Time Frame: 18 months
|
18 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Yin-Hsiu Chien, M.D., PhD., National Taiwan University Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2013
Primary Completion (ACTUAL)
October 1, 2016
Study Completion (ACTUAL)
October 1, 2016
Study Registration Dates
First Submitted
April 21, 2014
First Submitted That Met QC Criteria
April 23, 2014
First Posted (ESTIMATE)
April 25, 2014
Study Record Updates
Last Update Posted (ESTIMATE)
November 2, 2016
Last Update Submitted That Met QC Criteria
October 31, 2016
Last Verified
April 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 201308058RIND
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Spinal Muscular Atrophy
-
Marco CapogrossoRoche-GenentechRecruitingSpinal Muscular Atrophy Type 3 | Spinal Muscular Atrophy Type 4United States
-
Institut de Myologie, FranceInstitut RocheCompletedType 2 Spinal Muscular Atrophy | Type 3 Spinal Muscular AtrophyBelgium, France, Germany
-
Marco CapogrossoRoche-GenentechNot yet recruitingSpinal Muscular Atrophy | Spinal Muscular Atrophy Type 3 | SMA | Spinal Muscular Atrophy Type II | Spinal Muscular Atrophy 4United States
-
Novartis Gene TherapiesActive, not recruitingSMA | Spinal Muscular Atrophy Type II | Spinal Muscular Atrophy Type I | Spinal Muscular Atrophy Type IIIUnited States, Belgium, France, Japan, United Kingdom, Italy, Taiwan, Australia, Canada
-
Hoffmann-La RocheRecruitingSpinal Muscular Atrophy (SMA)Belgium, United States, Croatia, Japan, Netherlands, Spain, Canada, Poland, United Kingdom, Italy, Portugal, Australia
-
Northwell HealthCompletedAdult Spinal Muscular AtrophyUnited States
-
Hugh McMillanFamilies of Spinal Muscular Atrophy; Gwendolyn Strong FoundationTerminatedSpinal Muscular Atrophy (SMA)Canada
-
AveXis, Inc.United BioSource, LLCRecruitingSpinal Muscular Atrophy (SMA)Japan, United States, Korea, Republic of, Israel, Greece, Ireland, Portugal, Russian Federation, Taiwan
-
Hoffmann-La RocheAssociation Française contre les Myopathies (AFM), ParisCompletedSpinal Muscular Atrophy Type II | Spinal Muscular Atrophy Type III Non AmbulantGermany, Italy, France, Belgium, Poland, Netherlands, United Kingdom
-
Istanbul Medipol University HospitalIstanbul UniversityRecruitingNeuromuscular Diseases | Spinal Muscular Atrophy Type 3Turkey
Clinical Trials on newborn screening test for SMA
-
Kaohsiung Medical University Chung-Ho Memorial...The Chinese Foundation of Health; Taipei Institute of PathologyRecruiting
-
IRCCS Burlo GarofoloRecruiting
-
University of Wisconsin, MadisonUltragenyx Pharmaceutical IncCompletedPrader-Willi Syndrome | Angelman SyndromeUnited States
-
National Institute of Diabetes and Digestive and...National Center for Research Resources (NCRR)CompletedCystic Fibrosis | Lung Disease | Pseudomonas InfectionsUnited States
-
National Taiwan University HospitalCompleted
-
Columbia UniversityNew York State Department of Health; Illumina, Inc.; GeneDxRecruitingEarly Onset Genetic Conditions With Near Complete PenetranceUnited States
-
Affiliated Hospital of Nantong UniversityNantong Maternal and Child Health Care HospitalActive, not recruitingHearing Loss
-
Central Hospital, Nancy, FranceUnknown
-
Sequenom, Inc.ObstetrixCompleted
-
University of UtahAlbert Einstein College of Medicine; University of California, San Francisco; National Human Genome Research Institute (NHGRI) and other collaboratorsCompletedNeonatal Screening